LUNA18 + Cetuximab
Phase 1Terminated 1 views this week 0 watching💤 Quiet
Interest: 21/100
21
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Locally Advanced or Metastatic Solid Tumors
Conditions
Locally Advanced or Metastatic Solid Tumors
Trial Timeline
Oct 8, 2021 → Nov 13, 2025
NCT ID
NCT05012618About LUNA18 + Cetuximab
LUNA18 + Cetuximab is a phase 1 stage product being developed by Chugai Pharmaceutical for Locally Advanced or Metastatic Solid Tumors. The current trial status is terminated. This product is registered under clinical trial identifier NCT05012618. Target conditions include Locally Advanced or Metastatic Solid Tumors.
What happened to similar drugs?
5 of 20 similar drugs in Locally Advanced or Metastatic Solid Tumors were approved
Approved (5) Terminated (1) Active (14)
Hype Score Breakdown
Clinical
6
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05012618 | Phase 1 | Terminated |
Competing Products
20 competing products in Locally Advanced or Metastatic Solid Tumors